If you own Oracle (ORCL) or are thinking about adding to your position, the company’s latest moves in healthcare might have caught your attention. Oracle just signed a high-profile deal with NYC Health + Hospitals to bring its Fusion Cloud Applications to one of the largest public health systems in the US. In the same period, Oracle also added new capabilities to its Electronic Data Capture platform, making it easier for clinical researchers to handle sensitive health data and improve how new therapies get to market.
This combination signals more than just a series of press releases for Oracle. Over the past year, investors have seen momentum build as Oracle’s cloud business expands into high-stakes sectors. The stock is up 66% in the past year and has more than tripled over the past three years, with gains in the past three months reflecting renewed optimism around Oracle’s growth potential. As the company continues to land enterprise clients and roll out new technology in healthcare and other industries, the market is closely watching what ongoing innovation could mean for Oracle’s future earnings power.
But after this remarkable run, is Oracle actually undervalued given its growth prospects in healthcare, or has the market already priced in everything that is to come?
According to Nenad, the most widely followed narrative views Oracle as overvalued, with the current share price exceeding the narrative’s estimate of fair value by nearly 10 percent. The thesis centers on Oracle’s transition into a cloud-first, AI-driven enterprise IT leader, but questions whether recent growth and optimism have already been fully reflected in the price.
Oracle is a leading provider of enterprise IT solutions, focusing on databases, cloud computing, and enterprise software. Its primary revenue streams include: Cloud Services (Oracle Cloud Infrastructure, or OCI): Competing directly with AWS, Azure, and Google Cloud, OCI is growing rapidly, driven by its ability to handle enterprise workloads effectively. Enterprise Applications: Products like Oracle Fusion (ERP, SCM, HCM) and NetSuite dominate the enterprise resource planning (ERP) market.
Want to know which bold projections push Oracle’s fair value below today’s price? The narrative hints at aggressive assumptions for long-term cloud expansion and profitability. Intrigued by where this valuation draws the line between optimism and reality? The financial drivers behind this conclusion might surprise even Oracle bulls.
Result: Fair Value of $212.00 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, execution challenges and fierce competition in cloud computing could quickly shift the outlook for Oracle, despite its recent momentum.
Find out about the key risks to this Oracle narrative.
While the first approach sees Oracle as overvalued based on its stock price versus fair value, our DCF model paints a different picture. This suggests that shares could be trading well below intrinsic value. Which outlook will play out?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Oracle for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
If you see Oracle’s story differently or want to investigate the numbers for yourself, you can easily shape your own perspective in just a few minutes. Do it your way.
A great starting point for your Oracle research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
Don’t limit your opportunities. Use the Simply Wall Street Screener to uncover fresh companies that fit your strategy, before the crowd piles in.
-
Catch trends early with up-and-coming AI disruptors by checking out AI penny stocks, making waves in automation, analytics, and intelligent platforms.
-
Tap into tomorrow’s healthcare leaders. Find companies pioneering breakthroughs with healthcare AI stocks for smarter diagnostics, precision medicine, and digital health solutions.
-
Boost your portfolio’s income potential by browsing dividend stocks with yields > 3%, offering yields over 3% and strengthening your foundation for the long term.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ORCL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
link